Pharmacodynamic study of 131I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer

Liu,Xiang‑Yun; Su,Xin; Xie,Chen‑Jing; Li,Lei; Yan,Jian‑Yan; Sun,Zu‑Yue

doi:10.3892/etm.2015.2517

Pharmacodynamic study of 131I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer

Authors:
- Xiang‑Yun Liu
- Xin Su
- Chen‑Jing Xie
- Lei Li
- Jian‑Yan Yan
- Zu‑Yue Sun
View Affiliations

Affiliations: Key Laboratory of Exercise and Health Sciences, Shanghai University of Sport, Ministry of Education, Shanghai 200438, P.R. China, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
Published online on: May 26, 2015 https://doi.org/10.3892/etm.2015.2517
Pages: 572-578

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the inhibitory effect of 131I-labeled ovarian cancer antigen 215 (131I-CA215) antibody on human OC-3-VGH ovarian cancer. A subcutaneous transplanted tumor model of estrogen‑resistant human OC‑3‑VGH ovarian cancer in nude mice was established. The model mice were randomly divided into seven groups, which were the negative control (NC), positive control (PC; 60 mg/kg cyclophosphamide), high‑dose CA215 antibody (HA; 10 mg/kg), low‑dose CA215 antibody (LA; 2 mg/kg), high‑dose 131I‑CA215 antibody (131I‑HA; 10 mg/kg + 125 µCi), medium‑dose 131I‑CA215 antibody (131I‑MA; 6 mg/kg + 75 µCi) and low‑dose 131I‑CA215 antibody (131I‑LA; 2 mg/kg + 25 µCi) groups. Each group received intraperitoneal administration for 14 consecutive days. At 24 h after the final administration, the tumor was removed and weighed to calculate the tumor inhibition rate (TIR) and the relative tumor increase rate (T/C). Compared with the NC group, the HA group, as well as the 31I‑HA and 131I‑MA antibody groups, exhibited significantly inhibited tumor growth. The relative T/C values were 54, 30 and 48%, respectively, and the TIRs were 33.59, 64.89 and 45.80%, respectively. All differences were statistically significant. The difference between the HA and 131I‑HA groups also presented statistical significance. CA215 and 131I‑CA215 antibodies can markedly inhibit OC‑3‑VGH ovarian cancer. The high‑dose 131I‑CA215 antibody demonstrated a clear synergetic effect.

View Figures

View References

1	Luvero D, Milani A and Ledermann JA: Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
2	Zhang HY and Sun H: A study on relationship between Foxp3 gene and ovarian carcinoma. Zhong Guo Fu You Jian Kang Yan Jiu. 20:595–597. 2009.(In Chinese).
3	Chien CH, Wang FF and Hamilton TC: Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol. 99:11–19. 1994. View Article : Google Scholar : PubMed/NCBI
4	Frost SH, Bäck T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, Jensen H, Albertsson P and Lindegren S: Comparison of ²¹¹At-PRIT and ²¹¹At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm. 28:108–114. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zacchetti A, Coliva A, Luison E, et al: ¹⁷⁷Lu-labeled MOv18 as compared to ¹³¹I- or ⁹⁰Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol. 36:759–770. 2009. View Article : Google Scholar : PubMed/NCBI
6	Gustafsson AM, Bäck T, Elgqvist J, et al: Comparison of therapeutic efficacy and biodistribution of ²¹³Bi- and ²¹¹At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nucl Med Biol. 39:15–22. 2012. View Article : Google Scholar : PubMed/NCBI
7	Winter-Roach BA, Kitchener HC and Dickinson HO: Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. CD004706:2009. View Article : Google Scholar
8	Scholz C, Heublein S, Lenhard M, Friese K, Mayr D and Jeschke U: Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. BMC Res Notes. 5:5512012. View Article : Google Scholar : PubMed/NCBI
9	Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER and Verschraegen CF: Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol. 114:480–485. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ito K, Utsunomiya H, Niikura H, Yaegashi N and Sasano H: Inhibition of estrogen actions in human gynecological malignancies: new aspects of endocrine therapy for endometrial cancer and ovarian cancer. Mol Cell Endocrinol. 340:161–167. 2011. View Article : Google Scholar : PubMed/NCBI
11	Badia E, Docquier A, Busson M, Lapierre M, Pujol P, Balaguer P and Cavailles V: Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells. J Steroid Biochem Mol Biol. 132:176–185. 2012. View Article : Google Scholar : PubMed/NCBI
12	Nakayama K, Nakayama N, Katagiri H and Miyazaki K: Mechanisms of ovarian cancer metastasis: biochemical pathways. Int J Mol Sci. 13:11705–11717. 2012. View Article : Google Scholar : PubMed/NCBI
13	Azimian-Zavareh V, Hossein G and Janzamin E: Effect of lithium chloride and antineoplastic drugs on survival and cell cycle of androgen-dependent prostate cancer LNCap cells. Indian J Pharmacol. 44:714–721. 2012. View Article : Google Scholar : PubMed/NCBI
14	Stevens EV, Banet N, Onesto C, Plachco A, Alan JK, Nikolaishvili-Feinberg N, Midkiff BR, Kuan PF, Liu J, Miller CR, Vigil D, Graves LM and Der CJ: RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases. 2:202–210. 2011. View Article : Google Scholar : PubMed/NCBI
15	Palmer TD, Ashby WJ, Lewis JD and Zijlstra A: Targeting tumor cell motility to prevent metastasis. Adv Drug Deliver Rev. 63:568–581. 2011. View Article : Google Scholar
16	Song G, Ren J, Stojadinovic A, Chen W, Sahab Z, Fu SW and Man YG: Conjunction of tumor cells with lymphocytes: implications for tumor invasion and metastasis. Cancer Epidemiol. 36:354–363. 2012. View Article : Google Scholar : PubMed/NCBI
17	Petrovic M, Jankovic Z, Jaukovic Lj, et al: Clinical value of immunoscintigraphy in the rectal carcinomas: immunoscintigraphy of rectal carcinomas. Hepatogastroenterology. 60:1355–1359. 2013.PubMed/NCBI
18	Pagel JM, Appelbaum FR, Eary JF, et al: 131I-anti-CD45antibody plus busulfan and cyclophosphamide before allogeneic hematopoi-etic cell transplantation for treatment of acute myeloid leukemia in first re-mission. Blood. 107:2184–2191. 2006. View Article : Google Scholar : PubMed/NCBI
19	Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S and Hultborn R: Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of ²¹¹At-MX35F(ab')_₂ - a phase I study. J Nucl Med. 50:1153–1160. 2009. View Article : Google Scholar : PubMed/NCBI
20	Steiner M and Neri D: Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res. 17:6406–6416. 2011. View Article : Google Scholar : PubMed/NCBI
21	Harris M, Wang XG, Jiang Z, Phaeton R, Koba W, Goldberg GL, Casadevall A and Dadachova E: Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. Br J Cancer. 108:859–865. 2013. View Article : Google Scholar : PubMed/NCBI